Glaxo, say hello to another Advair rival in Germany and Sweden. Monday, Indian generics maker Cipla rolled out its copy of GSK's respiratory behemoth in the two European countries, and the company's CEO says more are on the way.
GlaxoSmithKline Chairman Christopher Gent says he'll step down at the end of 2015. But thanks to sweeping corruption allegations and a languishing stock price, shareholders want change at the top now, the Sunday Times reports.
GlaxoSmithKline's vaccine candidate for the deadly Ebola virus is ready to roll in human trials.
Initially, GSK officials had sounded distinctly skeptical about whether the vaccine could be ready in time to help contain the outbreak. But this morning there was a distinct can-do attitude in its approach to the crisis.
GlaxoSmithKline may be suffering from R&D setbacks, generic competition and corruption investigations in a dozen countries, but its HIV-oriented venture ViiV Healthcare is racking up new OKs. Friday, the company scored the FDA's blessing for a combo drug pegged at $5 billion in peak sales.
ViiV Healthcare, the HIV-focused venture majority-owned by GlaxoSmithKline, picked up FDA approval for a single pill that combines three antivirals and promises to challenge a leading treatment from Gilead Sciences.
Look under a pharma executive's bed, and you'll find monsters. What do those monsters look like, though? Accenture talked to C-suite executives at the world's biggest drugmakers and found that some of yesteryear's scary beings have moved on, leaving others to take front and center.
GlaxoSmithKline has rolled out a slew of respiratory meds lately, looking for newcomers to take up the torch as Advair sales fade. After notching three approvals on the COPD side, now, the pharma giant has a brand new asthma treatment on its hands in Arnuity.
GlaxoSmithKline's banner respiratory division picked up another FDA approval, securing the agency's blessing for an inhaled asthma treatment as it expands its stable of drugs for airway disorders.
The second round of bidding for a portfolio of aging GlaxoSmithKline drugs is about to begin, and a bevy of big names is expected to participate. The product portfolio--which includes such drugs as Paxil for depression, the antimalarial Malarone, and the fish-oil based Lovaza--brings in about £1 billion ($1.7 billion) in annual sales.